Navigation Links
Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
Date:1/6/2011

LITTLE FALLS, N.J., Jan. 6, 2011 /PRNewswire/ -- Regenicin's (OTC Bulletin Board: RGIN) Chief Operating Officer, Chris Hadsall, recently received the 2010 Citizenship Award for his volunteer work with the VET Foundation and disabled veterans. Mr. Hadsall received the award at the VFW's 111th Annual Founders Day Banquet in December.  Hadsall joins a long list of notable citizens and groups bettering the lives of Veterans in the Colorado community. 

Mr. Hadsall served our country as a decorated Operations and Intelligence Officer for the U.S. Marine Corps, where his responsibilities included supervision of operations, logistics and communications for over 150 marines. During his career in the USMC, Mr. Hadsall helped establish the Wounded Warrior Program, which provides unique services to wounded servicemen and founded the VET Foundation, an organization committed to helping service disabled veterans transition out of the military.  As a wounded veteran himself, Mr. Hadsall has been awarded the Purple Heart as well as the Iraqi Freedom Medal for his service to our country.  

"We congratulate Chris on his VFW Citizenship Award for his volunteer work with the Vet Foundation," says Randall McCoy, CEO of Regenicin. "We are honored and proud to have such an experienced, well respected citizen and former Marine heading up the operations for Regenicin."

About Regenicin

Regenicin, Inc., (OTC Bulletin Board: RGIN) is a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns.  The company is publicly traded with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement.  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition.  A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Announces Closing of Private Placement Transaction
2. Regenicin Changes Its Ticker Symbol to RGIN.OB
3. Regenicin Presentation Now Available Online at RetailInvestorConferences.com
4. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
5. Regenicin to Present Live at RetailInvestorConferences.com on November 4th
6. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
7. Regenicin to Form Scientific Advisory Board
8. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
9. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
10. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
11. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... , ... Do More with OHAUS , With the launch of the new ... weighing industry, to extending its expertise across the entire laboratory to a range of ... allowing for its customers to 'Do More' in the lab. , Efficiency ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy honey ... and tissues by delivering pollen and nectar containing nutrients necessary for growth and survival. ... healthy. , Many recent indicators point to a decline in honey bee health. Sick ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, a start-up ... of financing in the amount of $6 million. An investment vehicle affiliated with ... round. , The Series B funding will enable Cybrexa to complete the build-out ...
(Date:6/14/2017)... ... June 14, 2017 , ... Slone Partners welcomed a panel ... the executive search firm, “Building Value in Precision Medicine: Can We Overcome the ... Medicine, led an open discussion with expert panelists Troy Cox, CEO of Foundation ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):